Company
Caribou Biosciences ($CRBU)
Overview
Develops genome-edited allogeneic CAR-T cell therapies using CRISPR and chRDNA technology for patients with hematologic malignancies and other severe diseases.
Company
Develops genome-edited allogeneic CAR-T cell therapies using CRISPR and chRDNA technology for patients with hematologic malignancies and other severe diseases.